Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-611 in moderate-to-severe atopic dermatitis
NCT05641558Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSGJ-611 in atopic dermatitis (AD) (3 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Adverse events (AEs), vital signs, physical examination, electrocardiogram, and laboratory tests up to 24 Weeks. Started Oct 2021; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05641558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641558.